Optimizing Treatment Strategies in the
Management of Pulmonary Arterial Hypertension to Improve Patient
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session from the 2019 Spring Managed Care Forum. If you
participated in the live session, you are not eligible for
continuing education credits from this archive.
This activity is valid from July 1, 2019 to August 1, 2020
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
an educational grant from
Pulmonary Arterial Hypertension (PAH) is a progressive vascular
disorder where continuous, exceedingly high blood pressure exists in
the pulmonary artery – the blood vessel that carries blood from the
right ventricle of the heart into the small arteries in the lungs.
As a response to the elevated resistance of blood flow, the pressure
increases in the pulmonary artery and causes the right ventricle of
the heart to work harder to pump blood into the lungs. Over time,
the heart muscle can become so weakened that its ability to pump
enough blood through the body is lost, leading to heart failure –
the most common cause of death for PAH patients. Though relatively
rare – affecting approximately six per one million people – PAH is a
very serious, life threatening condition that worsens over time and
for which there is no cure. Approximately half of people diagnosed
with PAH will not live past five years. Additionally, PAH often
leads to the onset of comorbidities associated with the disease,
which not only puts the patient at higher risk but also increases
the costs to the healthcare system.
Because of the rarity of PAH, clinicians need to understand the risk
factors and symptoms of the disease, along with the importance of
diagnosing the patient in the appropriate class, so as to apply
treatment algorithms accordingly for pharmacologic decisions.
Treatment guidelines continue to be updated to find the best
treatment for the severity and individual nature of the disease in
each patient. These include monotherapy and combination therapies
that can include prostacyclin/prostacyclin analogues, endothelin
receptor antagonists, and phosphodiesterase-5 inhibitors. There are
also treatments that can that target a key molecular mechanism and
one of these is a director stimulator for soluble guanylate cyclase
in an oral form. Optimal treatment, accurate classification, and
risk stratification are keys to managing the patient’s health and
costs, as incorrect classification can lead to inappropriate
Upon completion of this
activity, participants will be able to:
Analyze the latest, evidence-based
guidelines for pulmonary arterial hypertension (PAH) for proper
diagnosis and treatment strategies
Discuss the different techniques in
PAH to improve and detect early diagnosis, including physical
exam and imaging modalities
Assess the clinical evidence on the
safety and efficacy of current and emerging treatment agents
Explore the role of combination
therapy in PAH management, including risk stratification
techniques that may assist in determining the most appropriate
Examine the strategies for
overcoming challenges in patients with PAH by taking a close
look at the prevention of drug interactions, reducing side
effects, management of comorbidities, and patient education
||Robert P. Frantz, MD
Professor of Medicine, Mayo Clinic College of Medicine
Director, Mayo Pulmonary Hypertension Clinic
serves on an advisory board for Gilead Sciences and ViiV
Healthcare. He has received grant/research support from
Janssen. His presentation has been reviewed for any
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
Will Williams has no relevant financial relationships to
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical education for
NAMCP designates this enduring material for a maximum of 1 AMA PRA
Category I creditsTM.
The American Association of Managed Care Nurses (AAMCN) is
accredited as a provider of continuing nursing education by the
American Nurses Credentialing Center’s Commission on Accreditation (ANCC).
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hour toward CMCN recertification
This presentation is supported by
an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue